Menu Search
Equities

Jiangsu Hengrui Pharmaceuticals Co Ltd

600276:SHH

Jiangsu Hengrui Pharmaceuticals Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)44.77
  • Today's Change-0.35 / -0.78%
  • Shares traded19.51m
  • 1 Year change+0.31%
  • Beta1.0340
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 17-Sep-24
Select bar for recommendation details.
Recommendations17-Sep-24
Buy13
Outperform11
Hold4
Sell1
Strong Sell0

Share price forecast in CNY

The 16 analysts offering 12 month price targets for Jiangsu Hengrui Pharmaceuticals Co Ltd have a median target of 54.50, with a high estimate of 120.00 and a low estimate of 41.90. The median estimate represents a 21.11% increase from the last price of 45.00.
High166.7%120.00
Med21.1%54.50
Low-6.9%41.90

Dividends in CNY

In 2023, Jiangsu Hengrui Pharmaceuticals Co Ltd reported a dividend of 0.20 CNY, which represents a 25.00% increase over last year. The 17 analysts covering the company expect dividends of 0.22 CNY for the upcoming fiscal year, an increase of 10.00%.
Div growth (TTM)25.00%
More ▼

Earnings history & estimates in CNY

On Aug 21, 2024, Jiangsu Hengrui Pharmaceuticals Co Ltd reported 2nd quarter 2024 earnings of 0.33 per share. This result was in line with the consensus of the 3 analysts following the company and exceeded last year's 2nd quarter results by 94.12%.
The next earnings announcement is expected on Oct 24, 2024.
Average growth rate+22.70%
Jiangsu Hengrui Pharmaceuticals Co Ltd reported annual 2023 earnings of 0.68 per share on Apr 17, 2024.
Average growth rate-3.12%
More ▼

Revenue history & estimates in CNY

Jiangsu Hengrui Medicine Co., Ltd. had 2nd quarter 2024 revenues of 7.60bn. This bettered the 6.65bn consensus of the 3 analysts covering the company. This was 38.43% above the prior year's 2nd quarter results.
Average growth rate+8.11%
Jiangsu Hengrui Medicine Co., Ltd. had revenues for the full year 2023 of 22.82bn. This was 7.26% above the prior year's results.
Average growth rate+0.47%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.